LENZ Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for LENZ Therapeutics (LENZ).

Price Target Range — 12 Quarters

Analyst Consensus — 7 Analysts

6Buy

1Hold

Consensus RatingBuy# Analysts7Avg. Consensus PT$30Upside to Avg. PT+825.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 19, 2026	Piper Sandler	Biren Amin	PT Cut	Neutral	$7→$5
Aug 12, 2026	Piper Sandler	Biren Amin	PT Cut	Neutral	$12→$7
Jul 7, 2026	HC Wainwright & Co.	Matthew Caufield	Maintained	Buy	$38
May 13, 2026	Citigroup	Yigal Nochomovitz	PT Cut	Buy	$26→$20
May 12, 2026	HC Wainwright & Co.	Matthew Caufield	PT Cut	Buy	$48→$38
May 12, 2026	Piper Sandler	Biren Amin	Downgrade	Overweight→Neutral	$39→$12
Apr 21, 2026	HC Wainwright & Co.	Matthew Caufield	PT Cut	Buy	$56→$48
Mar 26, 2026	Citigroup	Yigal Nochomovitz	PT Cut	Buy	$52→$26
Mar 25, 2026	B of A Securities	Jason Gerberry	PT Cut	Buy	$35→$29
Oct 20, 2025	Raymond James	Gary Nachman	PT Raise	Outperform	$40→$50
Oct 10, 2025	Piper Sandler	Biren Amin	PT Raise	Overweight	$51→$67
Aug 1, 2025	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$49→$52
Aug 1, 2025	HC Wainwright & Co.	Matthew Caufield	PT Raise	Buy	$48→$56
Jul 31, 2025	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$45→$49
Jul 31, 2025	Raymond James	Gary Nachman	PT Raise	Outperform	$39→$40
Jul 28, 2025	HC Wainwright & Co.	Matthew Caufield	PT Raise	Buy	$38→$48
May 8, 2025	HC Wainwright & Co.	Matthew Caufield	Maintained	Buy	$38
Apr 16, 2025	HC Wainwright & Co.	Matthew Caufield	Maintained	Buy	$38
Apr 14, 2025	Piper Sandler	Biren Amin	PT Raise	Overweight	$38→$51
Mar 20, 2025	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$44→$47

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Piper Sandler Maintains Neutral on LENZ Therapeutics, Lowers Price Target to $5

Piper Sandler analyst Biren Amin maintains LENZ Therapeutics (NASDAQ:LENZ) with a Neutral and lowers the price target from $7 to $5.

Benzinga Newsdesk

PRO
Piper Sandler Maintains Neutral on LENZ Therapeutics, Lowers Price Target to $7

Piper Sandler analyst Biren Amin maintains LENZ Therapeutics (NASDAQ:LENZ) with a Neutral and lowers the price target from $12 to $7.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on LENZ Therapeutics, Maintains $38 Price Target

HC Wainwright & Co. analyst Matthew Caufield reiterates LENZ Therapeutics (NASDAQ:LENZ) with a Buy and maintains $38 price target.

Benzinga Newsdesk

LENZ Therapeutics Eye Drug Profile Supports Blockbuster Opportunity: Analyst

LENZ Therapeutics partners with Arrotex to commercialize VIZZ in Australia and New Zealand as analysts remain focused on U.S. growth.

Vandana Singh

PRO
Citigroup Maintains Buy on LENZ Therapeutics, Lowers Price Target to $20

Citigroup analyst Yigal Nochomovitz maintains LENZ Therapeutics (NASDAQ:LENZ) with a Buy and lowers the price target from $26 to $20.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on LENZ Therapeutics, Lowers Price Target to $38

HC Wainwright & Co. analyst Matthew Caufield maintains LENZ Therapeutics (NASDAQ:LENZ) with a Buy and lowers the price target from $48 to $38.

Benzinga Newsdesk

LENZ Therapeutics Inc

뉴스

파트너 / 기고자

벤징가 글로벌

LENZ Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Piper Sandler Maintains Neutral on LENZ Therapeutics, Lowers Price Target to $5

PRO
Piper Sandler Maintains Neutral on LENZ Therapeutics, Lowers Price Target to $7

PRO
HC Wainwright & Co. Reiterates Buy on LENZ Therapeutics, Maintains $38 Price Target

LENZ Therapeutics Eye Drug Profile Supports Blockbuster Opportunity: Analyst

PRO
Citigroup Maintains Buy on LENZ Therapeutics, Lowers Price Target to $20

PRO
HC Wainwright & Co. Maintains Buy on LENZ Therapeutics, Lowers Price Target to $38

People Also Watch

People Also Watch

LENZ Therapeutics Inc

뉴스

파트너 / 기고자

벤징가 글로벌

LENZ Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROPiper Sandler Maintains Neutral on LENZ Therapeutics, Lowers Price Target to $5

PROPiper Sandler Maintains Neutral on LENZ Therapeutics, Lowers Price Target to $7

PROHC Wainwright & Co. Reiterates Buy on LENZ Therapeutics, Maintains $38 Price Target

LENZ Therapeutics Eye Drug Profile Supports Blockbuster Opportunity: Analyst

PROCitigroup Maintains Buy on LENZ Therapeutics, Lowers Price Target to $20

PROHC Wainwright & Co. Maintains Buy on LENZ Therapeutics, Lowers Price Target to $38

People Also Watch

People Also Watch

PRO
Piper Sandler Maintains Neutral on LENZ Therapeutics, Lowers Price Target to $5

PRO
Piper Sandler Maintains Neutral on LENZ Therapeutics, Lowers Price Target to $7

PRO
HC Wainwright & Co. Reiterates Buy on LENZ Therapeutics, Maintains $38 Price Target

PRO
Citigroup Maintains Buy on LENZ Therapeutics, Lowers Price Target to $20

PRO
HC Wainwright & Co. Maintains Buy on LENZ Therapeutics, Lowers Price Target to $38